Global 3D Printed Drugs Market Research and Forecast 2018-2027
The global 3D Printed Drugs market is still more research-based entity and with approval and commercialization of 3D printed drugs the market is expected to gain momentum in next decade (2017-2027). 3D printing as a technology in already has a broad reach and widely used in industries such as automobile, healthcare (primarily in dental and ortho), and retail. In the late 1980s, 3D printing (3DP) technology was developed at the Massachusetts Institute of Technology (MIT) as a rapid-prototyping technique. In this technology, an aqueous fluid is used to bind multiple layers of powder to create a wide range of drugs. 3D printed drugs are used to fuel innovation and progress across pharmaceutical industries. 3D-printed drugs may be useful for orphan drugs and/or personalized medications as these drugs are produced in small amount. In August 2015, the first 3D-printed drug approved by FDA, however, is produced in commercial scale. Aprecia pharmaceuticals introduced first 3D printed drug named Spritam (levetiracetam) uses a specially developed platform to produce rapidly disintegrating high-dose drugs that are easy to swallow.
Drawbacks of conventional pharmaceutical unit operations is driving the demand for 3D printed drugs across the globe. For instance, the conventional manufacturing unit operation involving milling, mixing, granulation and compression which can result in disparate qualities of the final products with respect to drug loading, drug release, drug stability and pharmaceutical dosage form stability. 3D printed drugs are being developed in such way that they do not alter the qualities of the final product. Further, high prevalence of chronic diseases such as arthritis, asthma, cancer and diabetes and integration of 3D printing with conventional pharmaceutical technologies are major factors in the growth of the market. Other factors that are contributing in the market growth include growing usage of 3D printing technology in healthcare and high demand of instantaneous soluble tablets.
However, high investment for continuous clinical development of 3D printing and complex clinical trial protocols will limit the growth of the market. Side effects of 3D printed drugs are also major concern in the market. Despite of this constraints, the market will show prominence growth during forecast period due to the increase in healthcare investment in emerging nations and rising demand of medicine customization and personalization.
The global 3D Printed Drugs can be segmented on the basis of dosage form, technology and region. On the basis of dosage form, the market is segmented into tablet, capsules, multi-drug implant, nanoparticles, solutions, nanosuspension, encapsulated within a polymer, and implant. Further, on the basis of technology, the market is bifurcated into inkjet printing, direct-write, zip dose, thermal inkjet (TIJ) printing, fused deposition modelling (FDM), powder bed printing and stereolithography (SLA). On the basis of geography, the market is segmented into North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW). North America holds a dominant position in the global 3D Printed Drugs research and development, followed by Europe. The increasing investments in research and development in 3D printed drug development is expected to drive the growth of the 3D Printed Drugs in the region. Asia Pacific is projected to exhibit a good growth in the global market over the forecast period.
There are very few players in the global 3D Printed Drugs market include Aprecia Pharmaceuticals LLC, Fabrx Ltd., and GlaxoSmithKline PLC. In order to sustain in the competitive market, these players adopt various strategies such as acquisitions, mergers, expansions, joint ventures, and product development, among others. For instance, GlaxoSmithKline PLC (GSK) has been investing in 3D printing technology for a few years now. Their R&D department dedicated to 3D printing uses the technology in a variety of ways including prototyping, packaging, and tissue sampling. GSK is developing 3D printing personalized medicine for each patient.
RESEARCH METHODOLOGY
The market study of 3D Printed Drugs is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Whitepapers, research-papers, and news blogs
Company websites and their product catalogue
Supplier Websites such as Alibaba, amazon for pricing analysis
The report is intended for hospitals, pharmaceuticals companies, government organizations for overall market analysis, and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.
MARKET SEGMENTATION:
Global 3D Printed Drugs is segmented on the basis of regional outlook and following segments:
Global 3D Printed Drugs Research and Analysis, By Dosage Form
Global 3D Printed Drugs Research and Analysis, By Technology
Global 3D Printed Drugs Research and Analysis, By Region
THE REPORT COVERS:
Comprehensive research methodology of global 3D Printed Drugs Market
This report also includes detailed and extensive market overview with key analyst insights
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations
Analysis of regional regulations and other government policies impacting the global 3D Printed Drugs Market
Insights about market determinants which are stimulating the global 3D Printed Drugs Market
Detailed and extensive market segments with regional distribution of forecasted revenues
Extensive profiles and recent developments of market players
Drawbacks of conventional pharmaceutical unit operations is driving the demand for 3D printed drugs across the globe. For instance, the conventional manufacturing unit operation involving milling, mixing, granulation and compression which can result in disparate qualities of the final products with respect to drug loading, drug release, drug stability and pharmaceutical dosage form stability. 3D printed drugs are being developed in such way that they do not alter the qualities of the final product. Further, high prevalence of chronic diseases such as arthritis, asthma, cancer and diabetes and integration of 3D printing with conventional pharmaceutical technologies are major factors in the growth of the market. Other factors that are contributing in the market growth include growing usage of 3D printing technology in healthcare and high demand of instantaneous soluble tablets.
However, high investment for continuous clinical development of 3D printing and complex clinical trial protocols will limit the growth of the market. Side effects of 3D printed drugs are also major concern in the market. Despite of this constraints, the market will show prominence growth during forecast period due to the increase in healthcare investment in emerging nations and rising demand of medicine customization and personalization.
The global 3D Printed Drugs can be segmented on the basis of dosage form, technology and region. On the basis of dosage form, the market is segmented into tablet, capsules, multi-drug implant, nanoparticles, solutions, nanosuspension, encapsulated within a polymer, and implant. Further, on the basis of technology, the market is bifurcated into inkjet printing, direct-write, zip dose, thermal inkjet (TIJ) printing, fused deposition modelling (FDM), powder bed printing and stereolithography (SLA). On the basis of geography, the market is segmented into North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW). North America holds a dominant position in the global 3D Printed Drugs research and development, followed by Europe. The increasing investments in research and development in 3D printed drug development is expected to drive the growth of the 3D Printed Drugs in the region. Asia Pacific is projected to exhibit a good growth in the global market over the forecast period.
There are very few players in the global 3D Printed Drugs market include Aprecia Pharmaceuticals LLC, Fabrx Ltd., and GlaxoSmithKline PLC. In order to sustain in the competitive market, these players adopt various strategies such as acquisitions, mergers, expansions, joint ventures, and product development, among others. For instance, GlaxoSmithKline PLC (GSK) has been investing in 3D printing technology for a few years now. Their R&D department dedicated to 3D printing uses the technology in a variety of ways including prototyping, packaging, and tissue sampling. GSK is developing 3D printing personalized medicine for each patient.
RESEARCH METHODOLOGY
The market study of 3D Printed Drugs is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Whitepapers, research-papers, and news blogs
Company websites and their product catalogue
Supplier Websites such as Alibaba, amazon for pricing analysis
The report is intended for hospitals, pharmaceuticals companies, government organizations for overall market analysis, and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.
MARKET SEGMENTATION:
Global 3D Printed Drugs is segmented on the basis of regional outlook and following segments:
Global 3D Printed Drugs Research and Analysis, By Dosage Form
Global 3D Printed Drugs Research and Analysis, By Technology
Global 3D Printed Drugs Research and Analysis, By Region
THE REPORT COVERS:
Comprehensive research methodology of global 3D Printed Drugs Market
This report also includes detailed and extensive market overview with key analyst insights
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations
Analysis of regional regulations and other government policies impacting the global 3D Printed Drugs Market
Insights about market determinants which are stimulating the global 3D Printed Drugs Market
Detailed and extensive market segments with regional distribution of forecasted revenues
Extensive profiles and recent developments of market players
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. MARKET DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATE
2.3.2. CHINA
2.3.3. INDIA
2.3.4. JAPAN
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. DRAWBACKS OF CONVENTIONAL PHARMACEUTICAL UNIT OPERATIONS
3.1.2. HIGH PREVALENCE OF CHRONIC DISEASES SUCH AS ARTHRITIS, ASTHMA, CANCER AND DIABETES
3.1.3. INTEGRATION OF 3D PRINTING WITH CONVENTIONAL PHARMACEUTICAL TECHNOLOGIES
3.1.4. GROWING USAGE OF 3D PRINTING TECHNOLOGY IN HEALTHCARE
3.1.5. HIGH DEMAND OF INSTANTANEOUS SOLUBLE TABLETS
3.2. RESTRAINTS
3.2.1. CONTINUOUS CLINICAL DEVELOPMENT OF 3D PRINTING REQUIRES HIGH INVESTMENT
3.2.2. COMPLEX CLINICAL TRIAL PROTOCOLS
3.3. OPPORTUNITIES
3.3.1. INCREASE IN HEALTHCARE INVESTMENT IN EMERGING NATIONS
3.3.2. RISING DEMAND OF MEDICINE CUSTOMIZATION AND PERSONALIZATION
4. MARKET SEGMENTATION
4.1. 3D PRINTED DRUGS BY DOSAGE FORMS
4.1.1. TABLET
4.1.2. CAPSULES
4.1.3. MULTI-DRUG IMPLANT
4.1.4. NANOPARTICLES
4.1.5. SOLUTIONS
4.1.6. NANOSUSPENSION
4.1.7. ENCAPSULATED WITHIN A POLYMER
4.1.8. IMPLANT
4.2. 3D PRINTED DRUGS BY TECHNOLOGY
4.2.1. INKJET PRINTING
4.2.2. DIRECT-WRITE
4.2.3. ZIP DOSE
4.2.4. THERMAL INKJET (TIJ) PRINTING
4.2.5. FUSED DEPOSITION MODELLING (FDM)
4.2.6. POWDER BED PRINTING
4.2.7. STEREOLITHOGRAPHY (SLA)
5. COMPETITIVE LANDSCAPE
5.1. MARKET SHARE ANALYSIS
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. APRECIA PHARMACEUTICALS, LLC.
7.2. CYCLE PHARMACEUTICALS LTD.
7.3. FABRX LTD.
7.4. GLAXOSMITHKLINE PLC
7.5. LINX PRINTING TECHNOLOGIES
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. MARKET DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATE
2.3.2. CHINA
2.3.3. INDIA
2.3.4. JAPAN
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. DRAWBACKS OF CONVENTIONAL PHARMACEUTICAL UNIT OPERATIONS
3.1.2. HIGH PREVALENCE OF CHRONIC DISEASES SUCH AS ARTHRITIS, ASTHMA, CANCER AND DIABETES
3.1.3. INTEGRATION OF 3D PRINTING WITH CONVENTIONAL PHARMACEUTICAL TECHNOLOGIES
3.1.4. GROWING USAGE OF 3D PRINTING TECHNOLOGY IN HEALTHCARE
3.1.5. HIGH DEMAND OF INSTANTANEOUS SOLUBLE TABLETS
3.2. RESTRAINTS
3.2.1. CONTINUOUS CLINICAL DEVELOPMENT OF 3D PRINTING REQUIRES HIGH INVESTMENT
3.2.2. COMPLEX CLINICAL TRIAL PROTOCOLS
3.3. OPPORTUNITIES
3.3.1. INCREASE IN HEALTHCARE INVESTMENT IN EMERGING NATIONS
3.3.2. RISING DEMAND OF MEDICINE CUSTOMIZATION AND PERSONALIZATION
4. MARKET SEGMENTATION
4.1. 3D PRINTED DRUGS BY DOSAGE FORMS
4.1.1. TABLET
4.1.2. CAPSULES
4.1.3. MULTI-DRUG IMPLANT
4.1.4. NANOPARTICLES
4.1.5. SOLUTIONS
4.1.6. NANOSUSPENSION
4.1.7. ENCAPSULATED WITHIN A POLYMER
4.1.8. IMPLANT
4.2. 3D PRINTED DRUGS BY TECHNOLOGY
4.2.1. INKJET PRINTING
4.2.2. DIRECT-WRITE
4.2.3. ZIP DOSE
4.2.4. THERMAL INKJET (TIJ) PRINTING
4.2.5. FUSED DEPOSITION MODELLING (FDM)
4.2.6. POWDER BED PRINTING
4.2.7. STEREOLITHOGRAPHY (SLA)
5. COMPETITIVE LANDSCAPE
5.1. MARKET SHARE ANALYSIS
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. APRECIA PHARMACEUTICALS, LLC.
7.2. CYCLE PHARMACEUTICALS LTD.
7.3. FABRX LTD.
7.4. GLAXOSMITHKLINE PLC
7.5. LINX PRINTING TECHNOLOGIES
LIST OF TABLES
TABLE 1 GLOBAL 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2027 ($ MILLION)
TABLE 2 GLOBAL 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY DOSAGE FORM 2017-2027 ($ MILLION)
TABLE 3 GLOBAL TABLET MARKET RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 4 GLOBAL CAPSULES MARKET RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 5 GLOBAL MULTI-DRUG IMPLANT MARKET RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 6 GLOBAL NANOPARTICLES MARKET RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 7 GLOBAL SOLUTIONS MARKET RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 8 GLOBAL NANOSUSPENSION MARKET RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 9 GLOBAL ENCAPSULATED WITHIN A POLYMER MARKET RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 10 GLOBAL IMPLANT MARKET RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 11 GLOBAL 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY TECHNOLOGY 2017-2027 ($ MILLION)
TABLE 12 GLOBAL INKJET PRINTING RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 13 GLOBAL DIRECT-WRITE RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 14 GLOBAL ZIP DOSE RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 15 GLOBAL THERMAL INKJET (TIJ) PRINTING RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 16 GLOBAL FUSED DEPOSITION MODELLING (FDM) RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 17 GLOBAL POWDER BED PRINTING RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 18 GLOBAL STEREOLITHOGRAPHY (SLA) RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 19 NORTH AMERICA 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2027 ($ MILLION)
TABLE 20 NORTH AMERICA 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY DOSAGE FORM 2017-2027 ($ MILLION)
TABLE 21 NORTH AMERICA 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY TECHNOLOGY 2017-2027 ($ MILLION)
TABLE 22 EUROPE 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2027 ($ MILLION)
TABLE 23 EUROPE 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY DOSAGE FORM 2017-2027 ($ MILLION)
TABLE 24 EUROPE 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY APPLICATION 2017-2027 ($ MILLION)
TABLE 25 APAC 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2027 ($ MILLION)
TABLE 26 APAC 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY DOSAGE FORM 2017-2027 ($ MILLION)
TABLE 27 APAC 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY TECHNOLOGY 2017-2027 ($ MILLION)
TABLE 28 REST OF THE WORLD 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY DOSAGE FORM 2017-2027 ($ MILLION)
TABLE 29 REST OF THE WORLD 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY TECHNOLOGY 2017-2027 ($ MILLION)
TABLE 1 GLOBAL 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2027 ($ MILLION)
TABLE 2 GLOBAL 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY DOSAGE FORM 2017-2027 ($ MILLION)
TABLE 3 GLOBAL TABLET MARKET RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 4 GLOBAL CAPSULES MARKET RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 5 GLOBAL MULTI-DRUG IMPLANT MARKET RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 6 GLOBAL NANOPARTICLES MARKET RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 7 GLOBAL SOLUTIONS MARKET RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 8 GLOBAL NANOSUSPENSION MARKET RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 9 GLOBAL ENCAPSULATED WITHIN A POLYMER MARKET RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 10 GLOBAL IMPLANT MARKET RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 11 GLOBAL 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY TECHNOLOGY 2017-2027 ($ MILLION)
TABLE 12 GLOBAL INKJET PRINTING RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 13 GLOBAL DIRECT-WRITE RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 14 GLOBAL ZIP DOSE RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 15 GLOBAL THERMAL INKJET (TIJ) PRINTING RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 16 GLOBAL FUSED DEPOSITION MODELLING (FDM) RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 17 GLOBAL POWDER BED PRINTING RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 18 GLOBAL STEREOLITHOGRAPHY (SLA) RESEARCH AND ANALYSIS 2017-2027 ($ MILLION)
TABLE 19 NORTH AMERICA 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2027 ($ MILLION)
TABLE 20 NORTH AMERICA 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY DOSAGE FORM 2017-2027 ($ MILLION)
TABLE 21 NORTH AMERICA 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY TECHNOLOGY 2017-2027 ($ MILLION)
TABLE 22 EUROPE 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2027 ($ MILLION)
TABLE 23 EUROPE 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY DOSAGE FORM 2017-2027 ($ MILLION)
TABLE 24 EUROPE 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY APPLICATION 2017-2027 ($ MILLION)
TABLE 25 APAC 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2027 ($ MILLION)
TABLE 26 APAC 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY DOSAGE FORM 2017-2027 ($ MILLION)
TABLE 27 APAC 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY TECHNOLOGY 2017-2027 ($ MILLION)
TABLE 28 REST OF THE WORLD 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY DOSAGE FORM 2017-2027 ($ MILLION)
TABLE 29 REST OF THE WORLD 3D PRINTED DRUGS RESEARCH AND ANALYSIS BY TECHNOLOGY 2017-2027 ($ MILLION)
LIST OF FIGURES
FIGURE 1 GLOBAL 3D PRINTED DRUGS SHARE BY DOSAGE FORM 2017 VS 2027 (IN %)
FIGURE 2 GLOBAL 3D PRINTED DRUGS SHARE BY TECHNOLOGY 2017 VS 2027 (IN %)
FIGURE 3 GLOBAL 3D PRINTED DRUGS SHARE BY GEOGRAPHY 2017 VS 2027 (IN %)
FIGURE 4 NORTH AMERICA 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 5 US 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 6 CANADA 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 7 EUROPEAN 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 8 UK 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 9 FRANCE 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 10 GERMANY 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 11 ITALY 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 12 SPAIN 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 13 ROE 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 14 ASIA PACIFIC 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 15 INDIA 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 16 CHINA 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 17 JAPAN 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 18 ROAPAC 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 19 REST OF THE WORLD 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
COMPANIES MENTIONED
1. APRECIA PHARMACEUTICALS, LLC.
2. CYCLE PHARMACEUTICALS LTD.
3. FABRX LTD.
4. GLAXOSMITHKLINE PLC
5. LINX PRINTING TECHNOLOGIES
FIGURE 1 GLOBAL 3D PRINTED DRUGS SHARE BY DOSAGE FORM 2017 VS 2027 (IN %)
FIGURE 2 GLOBAL 3D PRINTED DRUGS SHARE BY TECHNOLOGY 2017 VS 2027 (IN %)
FIGURE 3 GLOBAL 3D PRINTED DRUGS SHARE BY GEOGRAPHY 2017 VS 2027 (IN %)
FIGURE 4 NORTH AMERICA 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 5 US 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 6 CANADA 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 7 EUROPEAN 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 8 UK 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 9 FRANCE 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 10 GERMANY 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 11 ITALY 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 12 SPAIN 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 13 ROE 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 14 ASIA PACIFIC 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 15 INDIA 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 16 CHINA 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 17 JAPAN 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 18 ROAPAC 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
FIGURE 19 REST OF THE WORLD 3D PRINTED DRUGS SIZE 2017-2027 ($MILLION)
COMPANIES MENTIONED
1. APRECIA PHARMACEUTICALS, LLC.
2. CYCLE PHARMACEUTICALS LTD.
3. FABRX LTD.
4. GLAXOSMITHKLINE PLC
5. LINX PRINTING TECHNOLOGIES
